LY83583
Based on 1 publication(s) in Google Scholar
LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease.
For research use only. We do not sell to patients.
- Purity: 99.84%
- CAS No.: 91300-60-6
- Formula: C15H10N2O2
- Molecular Weight:250.26
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) LY83583
More
Biological Activity
LY83583 (1 μM, 4 d) induces morphological changes characteristic of senescence and senescence-associated β-galactosidase (SA-β-gal) staining at pH 6 in early-passage HDFs[1].
LY83583 (0.25-1.5 μM, 3 d) inhibits proliferation of early-passage HDFs, HCT116 and DLD1 colorectal cancer cell lines, MCF7 breast cancer cells and A-375 melanoma cells[1].
LY83583 (1 μM, 24-36 h) almost completely blocks HDF entry into the S phase after release from G1 phase synchronization by confluence, and inhibits DNA synthesis detected by BrdU incorporation[1].
LY83583 (1 μM, 3-6 h) induces p21 protein expression in HDFs[1].
LY83583 (1 μM, 6 h) shifts the phosphorylation status of pRb in HDFs toward the hypophosphorylated form[1].
LY83583 (1 μM, 2 h) inhibits SNP-induced cGMP synthesis in early-passage HDFs[1].
LY-83583 (10 μM, 1 h) stimulates cytochalasin B-inhibitable [3H]3-O-methyl-D-glucose uptake in Clone 9 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
LY83583 (100 μg dissolved in 5 μL 20% DMSO, i.c.v., once) significantly and persistently decreases REMS duration and increases NREMS duration in male rats[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Anesthetized cats (2-3.5 kg)[2]
-
Dosage:10 μM
-
Administration:topical application via cranial window, 15 min
-
Result:Inhibited Nitroprusside (HY-B0564)-induced vasodilation of cerebral arterioles or calcitonin gene-related peptide (CGRP)-induced vasodilation.
-
Animal Model:Male Sprague-Dawley rats (275-400 g)[4]
-
Dosage:100 μg dissolved in 5 μL 20% DMSO
-
Administration:i.c.v., once
-
Result:Decreased REMS duration and increased NREMS duration.
Increased EEG delta-wave power during NREMS and suppressed theta, alpha, beta-wave powers in NREMS/wakefulness.
Chemical Information
-
CAS No. 91300-60-6
-
Appearance Solid
-
Molecular Weight 250.26
-
Formula C15H10N2O2
-
Color Brown to red
-
SMILES
O=C1C=C(NC2=CC=CC=C2)C(C3=C1N=CC=C3)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : 200 mg/mL (799.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lodygin D, et al. Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. J Clin Invest. 2002 Dec;110(11):1717-27. [Content Brief]
[2]. Kontos HA, et al. Hydroxyl radical-dependent inactivation of guanylate cyclase in cerebral arterioles by methylene blue and by LY83583. Stroke. 1993 Mar;24(3):427-34. [Content Brief]
[3]. Prasad RK, et al. LY-83583 stimulates glucose transporter-1-mediated glucose transport independent of changes in cGMP levels. Eur J Pharmacol. 1999 Jan 29;366(1):101-9. [Content Brief]
[4]. Ribeiro AC, et al. The effects of intracerebroventricular application of 8-Br-cGMP and LY-83,583, a guanylyl cyclase inhibitor, on sleep-wake activity in rats. Brain Res. 2005 Jul 5;1049(1):25-33. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9958 mL | 19.9792 mL | 39.9584 mL | 99.8961 mL |
| 5 mM | 0.7992 mL | 3.9958 mL | 7.9917 mL | 19.9792 mL | |
| 10 mM | 0.3996 mL | 1.9979 mL | 3.9958 mL | 9.9896 mL | |
| 15 mM | 0.2664 mL | 1.3319 mL | 2.6639 mL | 6.6597 mL | |
| 20 mM | 0.1998 mL | 0.9990 mL | 1.9979 mL | 4.9948 mL | |
| 25 mM | 0.1598 mL | 0.7992 mL | 1.5983 mL | 3.9958 mL | |
| 30 mM | 0.1332 mL | 0.6660 mL | 1.3319 mL | 3.3299 mL | |
| 40 mM | 0.0999 mL | 0.4995 mL | 0.9990 mL | 2.4974 mL | |
| 50 mM | 0.0799 mL | 0.3996 mL | 0.7992 mL | 1.9979 mL | |
| 60 mM | 0.0666 mL | 0.3330 mL | 0.6660 mL | 1.6649 mL | |
| 80 mM | 0.0499 mL | 0.2497 mL | 0.4995 mL | 1.2487 mL | |
| 100 mM | 0.0400 mL | 0.1998 mL | 0.3996 mL | 0.9990 mL |
Powered by Bioz